secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001558370-23-006475
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences appoints Jeffrey Dayno as permanent President & CEO; Aronin returns to non-executive Chairman
--------------------------------------------------------------------------------

- Dr. Jeffrey Dayno appointed President and CEO effective April 24, 2023; also joins Board as Class I director.
- Dayno previously served as Interim President and CEO since Jan 6, 2023, and CMO since 2017.
- Jeffrey Aronin returns from Executive Chairman to non-executive Chairman of the Board.
- Dayno's employment agreement: base salary $650,000, target bonus 75% of base (up to 100% under certain circumstances).
- Dayno stated WAKIX could be a $1B+ narcolepsy franchise with additional $1B potential from other indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/hrmy-20230424x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-006475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer